We describe a protocol for the patient-directed registration of a three lead bipolar electrocardiogram by a smartwatch that functions identically to the Einthoven leads from standard electrocardiograms. This enables patients to record electrocardiograms on their own immediately after the onset of symptoms.
Cite this ArticleCopy Citation | Download Citations | Reprints and Permissions
Samol, A., Bischof, K., Luani, B., Pascut, D., Wiemer, M., Kaese, S. Patient Directed Recording of a Bipolar Three-Lead Electrocardiogram using a Smartwatch with ECG Function. J. Vis. Exp. (154), e60715, doi:10.3791/60715 (2019).
Translate text to:
Cardiac arrhythmias and cardiovascular diseases are a major public health problem in developed countries. A major goal in preventive medicine is the reduction of cardiovascular death by early detection of atrial fibrillation (AF), which may cause stroke, or early detection of life-threatening myocardial ischemia in acute coronary syndrome. Detection of arrhythmia is often challenging if symptoms occur when patients have no chance for immediate electrocardiogram (ECG) diagnostic testing, or if the observation time period is short or an immediate visit to their doctor is not possible. Smartwatches and other wearable devices are able to record a single lead ECG recording, but a single lead ECG is often not sufficient for diagnosis of cardiovascular disorders. Even diagnosis of AF can be difficult with only information from a single lead bipolar ECG. Some smart devices use photoplethysmography for detection of cardiac rhythm, but this technique can only give indirect hints of the underlying cardiac rhythm, is prone to interferences, and cannot be used for detection of myocardial ischemia. A three-lead bipolar ECG like the Einthoven leads used in regular ECGs can add useful information concerning arrhythmia detection or even diagnosis of other cardiovascular diseases like ischemia. Therefore, we describe a protocol for the patient-directed recording of an Einthoven three-lead ECG using a smartwatch.
Smartwatches or other so-called "wearable devices" show increasing popularity and a steeply rising daily use in Western countries. Nearly 80% of US-Americans own a smartphone and more than 10% have a smartwatch1. Due to a photoplethysmographic sensor using LED-light and photodiodes, some smartwatches can record pulse frequency and irregularities1. This feature enables the detection of arrhythmias, especially AF, with high diagnostic accuracy2,3. For authentic ECG arrhythmia detection, portable, handheld, and wearable ECG devices have been developed to enable smartphone-assisted ECG recordings. Nevertheless, these devices allow patient-activated recording of electrocardiograms only if the patients’ compliance for carrying the ECG device is extremely high4,5,6,7.
Thus, the optimal tool for a patient’s medical surveillance would be a smart device for daily use. Some last generation smartwatches enable a single-lead ECG recording comparable to bipolar lead Einthoven I from a standard 12-channel ECG using the backside of the watch as the positive and the crown as the negative electrode8. ECG recording is patient-controlled and activated if symptoms occur. Thereafter, an application creates a PDF document for further analysis by a healthcare professional. Nevertheless, using only a single-lead ECG for discrimination of P waves for diagnosis of sinus rhythm is sometimes insufficient9 for detection of the P wave and often multiple ECG leads are required5. In addition, multichannel ECG recording is mandatory for diagnosis of most acute or chronic structural heart diseases like myocardial infarction (MI), pulmonary embolism, or signs of acute heart failure.
More than 100 years ago, Einthoven developed a method for recording of a bipolar three- channel ECG10. This three-channel ECG offers the opportunity to identify the electrical heart axis and possibly the myocardial ischemia as well, especially in inferior regions of the myocardium11. Therefore, in clinical daily practice bipolar Einthoven leads I-III are essential parts of the 12-lead ECG and enable heart rhythm determination or detection of myocardial ischemia.
Early diagnosis and especially early treatment of myocardial infarction has improved substantially during recent decades. Nevertheless, especially early after the onset of symptoms, many patients hesitate to contact professional help. Thus, first medical contact and initiation of adequate treatment is often delayed12. Registration and transmission of a patient-directed ECG early after the onset of symptoms might accelerate specific treatment and thus enable a better patient outcome7. Until now, ischemia detection by smart devices is limited, because mainly single-lead (Einthoven I), or as in our study, maximal three-lead (Einthoven I-III) ECGs can be recorded, which only represent a limited area of the myocardium.
Several studies used patient-directed devices like portable ECG recorders, smartphones, and very recently smartwatches, for detection of AF in heart patients1,2,5,9. The Apple Heart Study and the WATCH AF trial used the photoplethysmographic LED-light sensor of the smartwatch for detection of an irregular or variable pulse, which correlates with arrhythmia like AF1,2. Insufficient signal quality was the limiting factor in these trials, leading to a high dropout rate2. Another smartwatch trial used photoplethysmography for AF detection, but also showed reduced diagnostic accuracy compared to regular ECGs13.
The detection of AF by the registration of pulse irregularities is the limiting factor of photoplethysmography, because heartbeat variabilities due to extra systoles or sinus arrhythmia may also cause pulse irregularities. Thus, recording of an ECG by a smartphone or smartwatch may increase the sensitivity and specificity of arrhythmia detection. Several smartphone compatible devices can record a bipolar single-lead ECG simulating Einthoven lead I5,9. In one study, a bipolar smartphone ECG device was used for AF screening9. In this trial, a small voltage of P waves in lead I led to incorrect AF determination, a limitation when only a single-lead ECG is available9. ECG devices for AF screening were also tested in hospitalized patients on cardiologic and geriatric wards5. Diagnostic accuracy of the automated algorithms was only suboptimal and additional 12-lead ECGs were often mandatory. Most of these devices have the limitation of only one ECG lead recording (Einthoven I), which is not always sufficient to ensure arrhythmia or repolarization detection.
Only one small case series of five patients demonstrated that a conventional 12 lead ECG is recordable by a conventional bipolar smartphone device after modification for unipolar lead recordings with ECG tabs and wires with alligator clips4. They showed ECG recordings with good signal quality, but the limiting factor is the need for device modifications that complicates patient-directed self-ECG recording.
In contrast, we performed the first study for recording an ECG with a smartwatch with the three bipolar Einthoven leads as a proof of concept in healthy subjects. We were able to show a high grade of consistency between the smartwatch leads and the Einthoven leads from a standard ECG using the following simple protocol.
This study was performed according to the Declarations of Helsinki and approved by the Ethics Committee of the Aerztekammer Westfalen-Lippe (reference number 2019-456).
- Instruct subjects on how to use the smartwatch for proper ECG recording.
2. Recording of a standard 12-lead ECG by a common device
- Use a common ECG device for standard ECG recording.
- Adjust the paper running speed to 50 mm/s.
- Perform the ECG recording after a 5 min resting period in a supine position.
- Place the right arm electrode near the right shoulder.
- Place the left arm electrode near the left shoulder.
- Place the right leg electrode near the right ankle.
- Place the left leg electrode near the left ankle.
- Place the V1 electrode in the fourth intercostal space at the right parasternal line.
- Place the V2 electrode in the fourth intercostal space at the left parasternal line.
- Place the V3 electrode between V2 and V4.
- Place the V4 electrode in the fifth intercostal space at the midclavicular line.
- Place the V5 electrode in the fifth intercostal space at the anterior axillary line.
- Place the V6 electrode in the fifth intercostal space at the mid-axillary line.
- Record a standard 12-lead ECG with the standard ECG device.
NOTE: The patient should not move during the ECG recording in order to prevent ECG artifacts.
3. Recording of Einthoven leads I-III by a smartwatch with ECG function
- Record smartwatch ECGs directly after recording the standard ECGs.
- Enable the application of the smartwatch for ECG recordings. A 30 s ECG will be recorded directly after proper skin contact with the smartwatch.
- Record Einthoven I by placing the back of the smartwatch on the left wrist and the right index finger on the crown (Figure 1A).
- Record Einthoven II by placing the back of the smartwatch on the left lower abdomen and the right index finger on the crown (Figure 1B).
- Record Einthoven III by placing the back of the smartwatch on the left lower abdomen and the left index finger on the crown (Figure 1C).
NOTE: The right and left index finger should not contact the skin of the left wrist or left lower abdomen for adequate ECG recording. The patient should not move during the ECG recording in order to prevent ECG artifacts.
4. Analysis of the ECGs
- Recorded smartwatch ECGs are digitally stored using the smartphone app.
- Use the "send PDF to your doctor" function to create a PDF document of every single smartwatch ECG lead. Print the digital smartwatch ECG on paper for comparison with the standard ECG on printed paper.
- Classify all recorded smartwatch ECGs as of moderate signal quality if at least three consecutive QRS-complexes show noise-free signal quality and there are no artifacts in the isoelectric lines between QRS-complexes.
- Classify smartwatch ECGs as of good signal quality if at least ten QRS-complexes show noise-free signal quality and there are no artifacts in isoelectric lines between QRS-complexes.
5. Statistical analysis
- Perform statistical analysis using IBM SPSS Statistics.
NOTE: Categorical variables are shown as absolute numbers and percentages. Continuous variables are presented as mean ± standard deviation. Differences of metric outcome variables were assessed by one way repeated analysis of variance (ANOVA) and paired t-test. In case of binary variables, the χ2-test was used.
In a cohort of 100 healthy subjects (66 female) we investigated the feasibility of our smartwatch recording protocol. The subjects' characteristics are shown in Table 1. After a short tutorial all volunteers managed the ECG recording procedure with the smartwatch. All 300 smartwatch ECGs were useable for further analysis with at least adequate signal quality for diagnostics purposes. Of the total ECGs, 277 (92%) were of good quality and 23 (8%) of moderate signal quality. Three blinded cardiologists were asked to assign the smartwatch ECGs to the corresponding Einthoven leads in each subject. They correctly assigned 278 (93%) smartwatch ECGs to the corresponding Einthoven lead I, II, and III from the 12-lead ECG (range from 93%–97%). All blinded cardiologists assigned the ECGs from eighty-nine participants (89%) correctly to the corresponding Einthoven leads. A comparison of the single-leads to the corresponding Einthoven leads is shown in Figure 2. Assignment errors occurred in 11 volunteers. In five of these subjects more than one cardiologist assigned the single-lead ECGs incorrectly to the corresponding Einthoven leads. Fleiss kappa analysis showed moderate interrater reliability (kappa = 0.437; p < 0.001). The intraclass correlation coefficient was 0.703. All assignment errors were made in subjects with comparable amplitudes and morphologies in the two smartwatch ECGs or the corresponding standard ECG leads. At least one ECG lead was assigned correctly in all participants by all the cardiologists. All assignment errors were made in the ECGs with good signal quality. Thus, there was no correlation between the quality of the ECG recordings and correct assignment. Assignment errors occurred in statistically older subjects (46 ± 10 vs.37 ± 11 years; mean ± SD). No other subject parameter listed in Table 1 was associated with an incorrect assignment.
Figure 1: Recording positions of the smartwatch for the three Einthoven leads. (A) Recording of Einthoven lead I between the left arm wrist and the right index finger. (B) Recording of Einthoven lead II between the left lower abdominal region and the right index finger. (C) Recording of Einthoven lead III between the left lower abdominal region and the left index finger. Please click here to view a larger version of this figure.
Figure 2: Comparison of a typical standard ECG with Einthoven I–III leads (black ECG curves) to the smartwatch ECGs (red ECG curves). Despite a different writing speed of 50 mm/s of the black ECG curves from the standard ECG and 25 mm/s of the red ECG curves of the smartwatch ECGs, the morphologies of the three channels are clearly identical. Please click here to view a larger version of this figure.
|QRS axis (°)||51±31||42±35||56±29||0.040|
|HR 12 lead ECG (bpm)||71±12||72±11||70±13||0.420|
|HR lead I (bpm)||71±11||72±9||70±11||0.301|
|HR lead II (bpm)||72±11||73±10||71±11||0.372|
|HR lead III (bpm)||72±11||74±10||70±11||0.096|
Table 1: Subject characteristics. BSA = body surface area; BMI = body mass index; HR = heart rate; lead I = Einthoven lead I; lead II = Einthoven lead II; lead III = Einthoven lead III.
Smart devices like smartphones and smartwatches are increasingly used in daily life and medical care1. These new devices and apps may have a significant impact on health awareness of the population, but their effective use needs to be tested in studies8. To the best of our knowledge, our group was the first to develop this method of single-lead ECG recordings corresponding to the conventional Einthoven ECG leads I-III using a smartwatch14.
An important part in the protocol for patient-directed ECG recording is sufficient instruction on the use of the smartwatch and the corresponding app. Patients need to be instructed where to place the back of the watch on the wrist of the left arm or left lower abdomen and the index finger of the left or right hand on the crown of the smartwatch. For optimization of smartwatch ECG quality, the user should be advised to not move during ECG recording in order to prevent ECG artifacts. Further, the index finger should not contact the wrist or abdomen. In addition, smartwatch ECG recording should be performed in a supine position, similar to standard ECG recordings. If patients detect insufficient ECG quality of the recorded ECG due to artifacts, optimization of skin contact may improve the signal quality. After a short tutorial, all of our 100 participants were able to perform the three-lead ECG recordings on their own by positioning the smartwatch in the required positions. Therefore, wider use of a smartwatch for patient-directed three-lead ECG recording may be feasible in the population at large after a short tutorial. This training may be performed by a short video clip or illustrated manual, for example. Our study cohort was middle-aged and may be more familiar with smart devices than older subjects. Therefore, in a cohort of older patients an appropriate use of a smartwatch for ECG recordings might be challenging due to difficulties in the use of the device or the app, the different positioning of the smartwatch, and a potential inability to lie still in a supine position due to comorbidities like Parkinson's disease. One recent study compared two handheld ECG devices and showed that approximately 7% of cardiology patients and 21.4% of geriatric patients did not manage correct use of the device5.
The quality of all the recorded smartwatch ECGs was sufficient for further evaluation. Good signal quality was found in 92% and moderate signal quality in 8% of smartwatch ECGs. Of our smartwatch ECGs, 93% were correctly assigned to the corresponding Einthoven leads I-III from 12-channel standard ECGs by all blinded cardiologists. Morphological and quantitative ECG parameters like P wave, QRS complex, and T wave of the smartwatch recordings were highly comparable to the corresponding standard ECG leads. Assignment errors occurred in older subjects, but physiognomic parameters and physical aspects like sex or electrical heart axis did not influence the correct ECG assignment. In older patients, assignment errors were not due to insufficient signal quality but were caused by comparable ECG morphologies in two of the three leads.
A limitation of the technology and protocol used our study is that several steps are required for recording a three-lead smartwatch ECG. The complexity of positioning the smartwatch and right or left index finger on the watch as well as the correct application of the required app may impede widespread use in the general population. Further, the smartwatch used in our study also requires use of a smartphone from the same company. Thus, this smartwatch cannot be used in combination with other commercially available smartphones or smart devices.
A limitation of our protocol is that we only performed a visual comparison of the recorded smartwatch leads with the standard ECGs. Until now, we have not developed a computer-based algorithm for comparison of the smartwatch bipolar ECGs with the standard Einthoven leads recorded by a standard ECG device. So far, we could only record Einthoven leads I-III with the smartwatch. Due to this, we could only record ECGs of a limited area of the heart encompassing the inferior and anterolateral myocardium. In addition, we have not performed measurements in patients with heart diseases. The use of patient-directed smartwatch ECG recordings in the wider population might improve and accelerate diagnosis of acute cardiac diseases and shorten duration to medical contact. Of note, users and patients should be reminded that smartwatch ECG recording does not replace a standard 12-lead ECG during a doctor's visit.
An advantage of the smartwatch is that patients with documented or presumed AF can carry them in daily life. Other smart devices for bipolar ECG recording need to be carried in addition to a smartphone, which may limit their wider use in the population. Multichannel smartwatch ECG recording may optimize monitoring heart rhythm in patients if the P waves cannot sufficiently be detected in lead I. Broad deployment of smartwatches for AF detection may improve medical treatment for this group of patients, because 25% of all strokes are caused by AF, which is the most frequent rhythm disorder in Western populations1. Further, many individuals are unknowingly at risk: in 18% of AF-related strokes, AF was diagnosed for the first time after the stroke1.
Recent studies1,2 demonstrated good accuracy of smartwatch AF detection based on photoplethysmography. The Apple Heart Study recorded pulse disorders by smartwatch photoplethysmography as a surrogate marker for the detection of AF1. The authors demonstrated that the smartwatch reliably recorded pulse disorders for unmasking asymptomatic AF1,9. The WATCH AF trial also used a smartwatch with photoplethysmography for AF detection2. This trial also showed a very high accuracy for AF detection by a smartwatch2. However, a limitation of the used algorithm was a high failure rate due to restricted signal quality2. An additional study with the smartwatch photoplethysmography technique confirmed the ability to record AF but also demonstrated reduced quality of AF detection compared to a standard ECG device13. A major limitation of the applied photoplethysmography in these studies is that pulse irregularities are used as a surrogate marker for AF detection. Cardiac extra systoles can also cause pulse disorders, which may be incorrectly interpreted as AF and therefore impede adequate AF detection. Therefore, the technique of smartwatch bipolar ECG recording may enhance the accuracy of detection of heart rhythm disorders compared to the smartwatch photoplethysmography technique. These true single-lead ECG recordings can be performed by several handheld electrocardiogram devices as additional tools for smartphones. One of these devices can record Einthoven lead I and showed a high sensitivity and specificity for AF detection in community-based AF screening9. Incorrect positive AF detection was caused by reduced P wave voltage in the only available lead Einthoven I9. An additional trial studied several one-lead ECG handheld devices for screening of AF in cardiologic and geriatric patients in hospital units5. This trial offered restricted diagnostic accuracy of the device algorithms and that supplemental 12-lead ECG recordings needed to be performed to increase diagnostic accuracy. A limitation of the one-lead ECG devices is that only Einthoven lead I can be applied, which impedes sufficient P wave detection. Further, these devices are used as an additional tool to a smartphone, which may limit wider use in the population, as the user must carry the ECG device in addition to the smartphone.
An advantage of the smartwatches is that they are worn like a normal watch, which may be useful in integrating these devices in daily life. This may contribute to a wider use of these smartwatches in the population, which may increase patient-directed ECG recording. Compared to the photoplethysmography of the older smartwatches and the single-lead ECG devices for smartphones, true bipolar three-lead ECG recording by the smartwatch in our study may improve detection of cardiac arrhythmias and myocardial ischemia as more ECG data are available. Our smartwatch ECG protocol may improve patient-directed AF detection and therefore optimize oral anticoagulation treatment of these patients, which in turn may decrease AF-related stroke rates. In addition, smartwatch ECG recordings may optimize the early detection of myocardial ischemia by the patients themselves, which may lead to improved initiation of adequate treatment and outcome in myocardial infarction15. Studies demonstrate that 75% of MI patients contact emergency medical services more than one hour after the onset of symptoms12. Studies showed that a delay between symptom onset and medical contact occurred because patients did not recognize that symptoms were caused by a heart disease or believed that the symptoms were harmless12. In this subgroup of MI patients, use of smartwatch ECG recording by the patients themselves may contribute to earlier detection of myocardial ischemia and diminish the time patients take to initiate medical contact, subsequently improving the treatment and outcome of MI.
Because our study evaluated the feasibility of recording a three-lead smartwatch ECG in healthy subjects, further studies should evaluate the feasibility of smartwatch ECG recordings in patients with cardiac disease. These studies should examine whether the three-lead smartwatch ECG recordings (Einthoven I-III) actually improve the detection of cardiac arrhythmia compared to a single-lead ECG recording (Einthoven I) and a 12-lead ECG from a standard device. The comparison of the diagnostic accuracy of the three-lead smartwatch ECG recordings should be performed in patients with AF, atrial flutter, and premature supraventricular contractions.
The authors have nothing to disclose.
This research received no external funding. We thank Lisa Tiedemann, Ester Krist and Tobias Anke for technical support.
|Apple Watch Series 4||Apple||Smartwatch with bipolar ECG function|
|IBM SPSS Statistics||IBM||version 25 for Mac|
|MAC 5500||GE Healthcare||Standard 12 channel ECG device|
- Turakhia, M. P., et al. Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart Study. American Heart Journal. 207, 66-75 (2019).
- Dorr, M., et al. The WATCH AF Trial: SmartWATCHes for Detection of Atrial Fibrillation. JACC Clinical Electrophysiology. 5, (2), 199-208 (2019).
- Hochstadt, A., et al. Continuous heart rate monitoring for automatic detection of atrial fibrillation with novel bio-sensing technology. Journal of Electrocardiology. 52, 23-27 (2019).
- Baquero, G. A., Banchs, J. E., Ahmed, S., Naccarelli, G. V., Luck, J. C. Surface 12 lead electrocardiogram recordings using smart phone technology. Journal of Electrocardiology. 48, (1), 1-7 (2015).
- Desteghe, L., et al. Performance of handheld electrocardiogram devices to detect atrial fibrillation in a cardiology and geriatric ward setting. Europace. 19, (1), 29-39 (2017).
- Samol, A., et al. Prevalence of unknown atrial fibrillation in patients with risk factors. Europace. 15, (5), 657-662 (2013).
- Nigolian, A., Dayal, N., Nigolian, H., Stettler, C., Burri, H. Diagnostic accuracy of multi-lead ECGs obtained using a pocket-sized bipolar handheld event recorder. Journal of Electrocardiology. 51, (2), 278-281 (2018).
- Foster, K. R., Torous, J. The Opportunity and Obstacles for Smartwatches and Wearable Sensors. IEEE Pulse. 10, (1), 22-25 (2019).
- Lau, J. K., et al. iPhone ECG application for community screening to detect silent atrial fibrillation: a novel technology to prevent stroke. International Journal of Cardiology. 165, (1), 193-194 (2013).
- Einthoven, W., Fahr, G., De Waart, A. On the direction and manifest size of the variations of potential in the human heart and on the influence of the position of the heart on the form of the electrocardiogram. American Heart Journal. 40, (2), 163-211 (1950).
- Burch, G. E. History of precordial leads in electrocardiography. European Journal of Cardiology. 8, (2), 207-236 (1978).
- Leslie, W. S., Urie, A., Hooper, J., Morrison, C. E. Delay in calling for help during myocardial infarction: reasons for the delay and subsequent pattern of accessing care. Heart. 84, (2), 137-141 (2000).
- Tison, G. H., et al. Passive Detection of Atrial Fibrillation Using a Commercially Available Smartwatch. JAMA Cardiology. 3, (5), 409-416 (2018).
- Samol, A., et al. Recording of Bipolar Multichannel ECGs by a Smartwatch: Modern ECG Diagnostic 100 Years after Einthoven. Sensors (Basel). 19, (13), (2019).
- Avila, C. O. Novel Use of Apple Watch 4 to Obtain 3-Lead Electrocardiogram and Detect Cardiac Ischemia. Permanente Journal. 23, (2019).